Last reviewed · How we verify
baclofen/amitriptyline/ketamine gel
This triple-agent topical gel combines a GABA-B agonist (baclofen), a tricyclic antidepressant (amitriptyline), and a dissociative anesthetic (ketamine) to provide multimodal analgesia for neuropathic pain.
This triple-agent topical gel combines a GABA-B agonist (baclofen), a tricyclic antidepressant (amitriptyline), and a dissociative anesthetic (ketamine) to provide multimodal analgesia for neuropathic pain. Used for Cancer-related neuropathic pain (Phase 3).
At a glance
| Generic name | baclofen/amitriptyline/ketamine gel |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Drug class | Multimodal analgesic combination gel |
| Target | GABA-B receptor, norepinephrine/serotonin transporters, NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology (cancer-related neuropathic pain) |
| Phase | Phase 3 |
Mechanism of action
Baclofen acts as a GABA-B receptor agonist to reduce neuronal excitability and muscle spasticity. Amitriptyline inhibits reuptake of norepinephrine and serotonin, enhancing descending pain inhibition. Ketamine blocks NMDA receptors, reducing central sensitization and neuropathic pain signaling. The combination targets pain through multiple mechanisms when applied topically.
Approved indications
- Cancer-related neuropathic pain (Phase 3)
Common side effects
- Local skin irritation or erythema
- Dizziness or sedation (systemic absorption)
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: